drugset

drugset / Trial / NCT05465590

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

NCT05465590 ↗

Phase 0 Withdrawn Mainline Biosciences, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.

Timeline

Start: 2022-12
Primary completion: 2024-11
Completion: 2024-12

Outcome

Outcome not reported

Stopped (Business): “The study was terminated due to Sponsor decision”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MB1707	Peptide	0.3 mg/kg	Intravenous

Indications